Efficacy and safety profile of dMMR/MSI immunotherapy in metastatic colorectal cancer in real-world clinical practice
Introduction. Deficiency of the mismatch repair system (dMMR) and microsatellite instability (MSI) occur in only 4–5% of patients with metastatic colorectal cancer (mCRC), but this molecular subgroup is characterized by high sensitivity to immune checkpoint inhibitors. Data on the efficacy and safety of such thera...